Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS203 in Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
NCT05618327Phase 1Active, not recruiting
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Feb 2023
- Primary completion
- Dec 2026
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of JS203 in B-cell non-Hodgkin lymphoma (B-NHL), sponsored by Shanghai Junshi Biosciences Co., Ltd. Primary endpoints: Maximum Tolerated Dose at 1.5 years and Recommended Phase 2 Dose at 1.5 years. Started Feb 2023; status: active, not recruiting.
02
Drugs
JS203
03
Conditions
B-cell non-Hodgkin lymphoma (B-NHL)
Beyond the preview
Go deeper on NCT05618327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05618327.